Comparison of long‐term prognosis between non‐obese and obese patients with non‐alcoholic fatty liver disease. Issue 10 (24th August 2022)

• Record Type: Journal Article
• Authors: Iwaki, Michihiro; Kessoku, Takaomi; Tanaka, Kosuke; Ozaki, Anna; Kasai, Yuki; Yamamoto, Atsushi; Takahashi, Kota; Kobayashi, Takashi; Nogami, Asako; Honda, Yasushi; Ogawa, Yuji; Imajo, Kento; Oyamada, Shunsuke; Kobayashi, Noritoshi; Aishima, Shinichi; Saito, Satoru; Nakajima, Atsushi; Yoneda, Masato
• Is Part Of: JGH open. Volume 6:Issue 10(2022)
• Page Start: 696
• Page End: 703
• Publication Date: 2022-08-24
• Subjects: clinical events -- non‐alcoholic fatty liver disease -- non‐obese non‐alcoholic fatty liver disease
• DOI: 10.1002/jgh3.12808
• Languages: English
• ISSNs: 2397-9070

Abstract

Abstract: Background and Aim: Non‐alcoholic fatty liver disease (NAFLD) can progress in non‐obese patients as in obese patients. Reports on long‐term prognosis in non‐obese NAFLD patients are controversial. Therefore, we aimed to examine the long‐term prognosis of non‐obese patients with NAFLD. Methods: This single‐center, retrospective cohort study enrolled biopsy‐proven non‐obese and obese NAFLD patients between January 2002 and December 2011 and followed them up until 31 March 2021, for death and clinical events (cardiovascular and liver‐related events and extrahepatic cancers). Results: Of the 223 NAFLD patients, 58 (26.0%) were non‐obese. Compared with obese patients, they had a lower fibrosis stage (0.8 ± 0.80 vs 1.2 ± 0.91; P = 0.004), milder lobular inflammation (0.9 ± 0.7 vs 1.1 ± 0.7; P = 0.02), and significantly lower serum creatinine, total bilirubin, ferritin, and type IV collagen 7S and higher high‐density lipoprotein levels. After a median follow‐up of 8.9 years, no significant difference was noted in mortality between the two groups (2 [3.4%] non‐obese vs 5 [3.0%] obese; log‐rank test, P = 0.63). Twelve patients (20.7%) in the non‐obese group and 32 (19.4%) in the obese group had clinical events. Although the obese group had a higher incidence of clinical events during the first 10 years of follow‐up, the non‐obese group had a higher incidence after that (log‐rank test, P = 0.67). The non‐obese group had a high incidence of malignancy (9 [15.5%] non‐obese vs 14 [8.3%] obese; P = 0.13). Conclusion: Non‐obese NAFLD does not necessarily have a good prognosis, and some cases have a poor prognosis such as extrahepatic cancers. Further validation is required in the future. Abstract : Non‐obese non‐alcoholic fatty liver disease does not necessarily have a good prognosis, and some cases have a poor prognosis such as extrahepatic cancers.